Clinical Trials
259 trialsNCT03745326 2026-05-19
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04034251 2026-05-05
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04166383 2026-03-10
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03772925 2026-03-03
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05554354 2026-03-03
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04258566 2026-02-02
Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
National Institutes of Health Clinical Center (CC)
Phase NA Terminated
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02948426 2026-01-08
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05918055 2025-12-02
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04541017 2025-10-16
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT04616547 2025-10-03
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
Phase 2 Terminated
NCT05198843 2025-10-03
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04108858 2025-10-01
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT05148234 2025-09-30
BMS-986253 in Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04936230 2025-08-17
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03724084 2025-06-18
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT04406857 2025-02-26
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04370834 2025-02-04
Tocilizumab for Patients With Cancer and COVID-19 Disease
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04538378 2025-01-27
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01217411 2024-11-19
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01413750 2024-11-12
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02097225 2024-10-16
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02649868 2024-07-11
LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02876640 2024-06-18
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04027946 2024-04-16
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03345784 2024-02-20
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02899728 2023-10-17
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03366103 2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT03592641 2023-10-17
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03190967 2023-10-11
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04566133 2023-08-21
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02059265 2023-08-01
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02917629 2023-03-08
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01712659 2023-01-10
Ruxolitinib for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02408887 2022-09-27
Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated